Search results for "Highlights"

Results 111 - 120 of about 379 for "Highlights".
Sort by: Relevance | Newest | Oldest

Metabolic surgery associated with lower risk for MACE in obese adults with type 2 diabetes

Patients with diabetes and obesity who had metabolic surgery were matched in a 1:5 ratio to those who received usual care, with incidence of a major cardiovascular event (MACE) as the primary outcome.
13 Sep 2019

SGLT-2 inhibitors linked to lower risk of cardiac events compared with DPP-4 inhibitors

A retrospective study of Canadian and British patients with type 2 diabetes found lower rates of cardiovascular death among those taking sodium-glucose cotransporter-2 (SGLT-2) inhibitors than in matched patients who took dipeptidyl peptidase-4 (DPP-4) inhibitors.
9 Oct 2020

Diabetes patients with healthy lifestyles appear to have low, no excess CVD risk, study finds

An accompanying editorial called for broader international efforts to target cardiovascular risk through programs that encourage healthy lifestyles.
9 Aug 2019

Different diabetes phenotypes associated with varying prevalence of complications

Patients were categorized into five groups: mild age-related diabetes, mild obesity-related diabetes, severe autoimmune diabetes, severe insulin-resistant diabetes, and severe insulin-deficient diabetes.
9 Aug 2019

Weight loss through gastric bypass or diet improved insulin sensitivity in patients with type 2 diabetes

Results from this small study suggest that reducing adipose tissue volume, by whatever means, will improve blood glucose control in patients with type 2 diabetes, an accompanying editorial noted.
11 Sep 2020

Young adults with diabetes have less favorable cardiometabolic risk profile versus those without, study finds

Compared to young adults without diabetes, those with diabetes were more likely to have obesity, elevated lipids, or hypertension and were less likely to report being physically active or consuming a healthy diet.
12 Jul 2019

Cardiology guidance supports use of SGLT-2 inhibitors, GLP-1 receptor agonists for CV benefits in diabetes

Evidence on sodium-glucose cotransporter-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists indicates that these drugs can be used not just for glucose control but for cardiovascular (CV) risk reduction in patients with type 2 diabetes, according to a new expert pathway.
14 Aug 2020

Patient-centered diabetes care varies in intensity by both disease- and patient-related factors

Patients were more likely to choose more intensive care after an annual consultation if they had a high level of education, if they were concerned about illness, if they had set goals for their care, and if they had comorbid conditions.
12 Jul 2019

AHA offers new guidance on treating diabetes and heart failure

A scientific statement from the American Heart Association and the Heart Failure Society of America describes new approaches to medications, lifestyles, and the importance of multidisciplinary care that includes physicians and other clinicians.
14 Jun 2019

ADA updates standards of care related to CV, renal health in type 2 diabetes

The updates were based on findings from the industry-funded CREDENCE (Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy) trial.
14 Jun 2019

Result Page: Prev   7   8   9   10   11   12   13   14   15   16   Next